Xu Danfeng, associate professor, male, born in 1965. 10, associate professor and deputy chief physician of urology in Changzheng Hospital of Second Military Medical University, Ph.D. student, director of urology in Changzheng Hospital of Second Military Medical University, secretary of Party branch and director of urology center of the whole army. Member of the Standing Committee of Urology Branch of Chinese Medical Association, member of the National Expert Group on Minimally Invasive Treatment of Urology, and member of the Male Branch of Shanghai Medical Association. Mainly engaged in the clinical research of minimally invasive treatment technology in urology, specializing in minimally invasive treatment of prostate diseases, urolithiasis, urogenital tumors and other diseases, and also having deep attainments in the basic and clinical treatment research of kidney tumors, bladder tumors and prostate cancer. He has rich experience in various operations of common and frequently-occurring diseases in urology, such as radical operation of renal cancer and renal pelvis cancer. In Shanghai, he took the lead in completing landmark and difficult operations such as laparoscopic total cystectomy, laparoscopic radical prostatectomy, laparoscopic partial nephrectomy and transurethral resection of huge prostate. In 2004 and 2005, he served as the chairman of the endoscopic therapy branch of the national urology annual meeting. Editor-in-chief of monograph 1 department, participated in editing 6 editorials, published more than 20 papers in core journals, and won the second prize of national scientific and technological progress 1 item, the first prize of military medical achievements 1 item, and the second and third prizes of military scientific and technological progress 1 item. With the signature of 1 and No.2, he got a fund of 2.65 million yuan, won the title of excellent party member and model party branch secretary of our college, and won the personal third-class merit 1 time. He won the first clinical newcomer award, the first medical new technology and new therapy award, and the second Long March Nova Award.